ImmPACT Bio Overview
ImmPACT Bio is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company's logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent "on-target off-tumor" toxicities, and overcome the immunosuppressive tumor microenvironment. The company's technology is based on the work of Yvonne Chen, PhD, and Antoni Ribas, MD, PhD, both from University of California, Los Angeles, and Gideon Gross, PhD, from the MIGAL-Galilee Research Institute.
Cumulative Funding Raised Over Time ($)
Latest News
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
growth-positive
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Lyell Immunopharma, Inc. announced its acquisition of ImmPACT Bio USA Inc., a clinical-stage biotechnology company. This acquisition strengthens Lyells clinical pipeline by adding ImmPACTs dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314, designed for hematologic malignancies. The transaction involves $30 million in cash and 37.5 million shares of Lyell common stock, with additional contingent shares based on clinical milestones. Lyell plans to focus on next-generation CAR T-cell therapies, discontinuing some earlier-stage programs. The acquisition is expected to enhance Lyells capabilities in developing durable cancer therapies, with a pivotal trial for IMPT-314 anticipated in 2025. The deal is expected to close in the fourth quarter of 2024.
Acquisition
growth-positive
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus | BioSpace
ImmPACT Bio USA INC. has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its ongoing Phase 1b/2 study evaluating IMPT-514 for the treatment of refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). IMPT-514 is a potentially first-in-class CD19/CD20 bispecific CAR T-cell therapy designed for deep and extensive depletion of autoreactive immune cells. Initial efficacy and safety data from the trial is expected in the second half of 2024.
Investment
growth-positive
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
ImmPACT Bio USA, Inc. has appointed Biren Amin, M.B.A., to its board of directors. Amin brings decades of experience in capital markets, finance, and corporate strategy. His expertise will be valuable as the company continues to build and advance its pipeline of next-generation CAR T-cell therapies for cancer treatment. ImmPACT Bio is rapidly advancing its novel bispecific CAR to treat aggressive B-cell lymphoma into Phase 1/2 clinical trials. Amins knowledge of finance and capital markets will help implement strategies to grow the company and move its therapies through clinical trials. ImmPACT Bio aims to develop transformative oncology medicines for cancer patients in need of new treatment options.
Management Changes
growth-positive
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
ImmPACT Bio has received clearance from the FDA for its first Investigational New Drug (IND) application for IMPT-314, a bispecific CAR T-cell therapy targeting B-cell lymphomas. The company plans to initiate a Phase 1/2 clinical trial in early 2023. The therapy has shown promising results in an investigator-led study, with 70% of patients achieving a complete response. ImmPACT Bio raised $111 million in a Series B financing round to support its cell therapy development and manufacturing facilities. The company is also investigating CAR T-cell technologies for solid tumors.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $137M |
| Last funding | $8M |
| Stage | Acquired |
| Rounds | 5 |
| Investors | 10 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | immpact-bio.com/ |
| Careers | Careers page |
Locations
Rehovot, Israel
8501 Fallbrook Ave, West Hills, CA 91304, USA
Photos & Videos
No files yet
